Welcome to our dedicated page for BIO-PATH HOLDINGS SEC filings (Ticker: BPTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIO-PATH HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIO-PATH HOLDINGS's regulatory disclosures and financial reporting.
Bio-Path Holdings, Inc. (BPTH) reports for the six months ended June 30, 2026 as a clinical and preclinical RNAi nanoparticle drug developer with four antisense candidates for cancer and obesity but no revenue and an accumulated deficit of $129,081 thousand.
Net loss narrowed to $2,906 thousand from $7,449 thousand a year earlier, mainly because research and development fell to $916 thousand and general and administrative to $318 thousand after pausing key trials and cutting overhead. However, total assets were only $6 thousand (cash $2 thousand) versus liabilities of $9,693 thousand, producing shareholders’ deficit of $9,687 thousand and a disclosed substantial doubt about continuing as a going concern.
The company converted $40 thousand of accrued obligations into 40,000 thousand common shares, raised modest equity under its Tier 1 Regulation A offering and via a small private placement, and entered short-term promissory notes now in default and accounted for with a $778 thousand derivative liability. Recent actions include launching an AI-driven “digital asset treasury 2.0” with a Coinbase account, intending to allocate up to 50% of new capital to crypto, and negotiating to restart Phase 2 AML trials at MD Anderson after paying past-due clinical balances.
Bio-Path Holdings, Inc. reported unregistered equity sales under its Tier 1 Regulation A program, selling 466,100 and 489,200 common shares for net proceeds of $13,983 and $14,676, with capacity to raise an additional $571,341. The board approved a new Series B Preferred stock class with 5,000,000 authorized shares, each convertible into 1,000 common shares, voting on an as-converted basis and carrying a par value of $0.01.
The company describes a strategic turnaround that may include restarting drug trials, monetizing its oncology intellectual property, and building a digital asset treasury. MD Anderson Cancer Center agreed to restart Phase 2 AML trials if Bio-Path pays past-due balances of $292,264.21 and $63,286.55. Bio-Path opened a Coinbase account and may allocate up to 50% of capital raised to crypto opportunities, acquired a majority stake in Himalaya Technologies, Inc. via Series B Preferred issuances valued at $670,260, and issued additional Series B shares to its CEO for software. It added altFINS founder Richard Fetyko to its advisory board and signed an LOI contemplating 2,500,000 common share equivalents and an option to buy up to 22% of altFINS for two million euros; multiple initiatives remain subject to payments, definitive agreements, and successful capital raising.
Bio-Path Holdings disclosed several strategic changes and capital-related steps. The company issued a shareholder update announcing a growth-focused repositioning, brought on new scientific advisors, engaged advisors to connect with strategic and financial investors, and canceled a previously approved 1-for-30 reverse stock split.
The Board approved a “digital asset treasury 2.0” program using AI to trade and accumulate multiple L1 and L2 blockchains and authorized opening an account with Coinbase or similar exchanges to buy, sell, and hold cryptocurrencies acquired through various channels. The Board also approved assigning to the company up to $10,000,000 of a $57,903,750 judgment, plus stated interest amounts, previously awarded to CEO Vikram Grover, with consideration to be paid in company securities when the judgment is monetized, aiming for accretion to shareholders. The company cautions there is no assurance Mr. Grover will obtain custodianship needed to complete related transactions.
Bio-Path Holdings reports a sharply reduced first-quarter loss but remains in severe financial distress. For the three months ended March 31, 2026, operating expenses fell to $0.3 million from $3.2 million a year earlier as research and development dropped to $0.04 million and general and administrative to $0.3 million, reflecting an operational pause and furloughs. Net loss narrowed to $0.3 million, or $0.03 per share, versus $2.9 million, or $0.40 per share, in the prior-year quarter.
Total assets were only $0.7 million against $9.2 million of liabilities, leaving shareholders’ deficit at $8.5 million. The company discloses that approximately $0.1 million of cash at March 31, 2026 is not enough to fund the next 12 months and states that substantial doubt exists about its ability to continue as a going concern. Several short-term promissory notes are already in default and carry default repayment at 150% of principal plus 22% default interest, with deep-discount conversion rights into common stock.
The report also notes that the March 31, 2026 financial statements are unaudited and have not been reviewed by an independent registered public accounting firm, so the filing is considered deficient. Subsequent to quarter-end, Bio-Path raised small amounts of equity under a Tier 1 Regulation A offering and issued 40 million common shares to Steel Giants Advisors LLC for accrued consulting compensation and wages due to the CEO, massively increasing the share count from 9.3 million at March 31, 2026 to over 50 million shares outstanding by May 20, 2026, and significantly diluting existing holders.
Bio-Path Holdings, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the period ended March 31, 2026 will be late while it compiles information for the year ended December 31, 2025. The notification is signed by Vikram Grover and dated May 15, 2026.
Bio-Path Holdings, Inc. reported several corporate updates. The company’s domestication to Wyoming was approved by the Wyoming Secretary of State on March 5, 2026, and it filed an amendment creating a new Series S Preferred Stock class with 51 authorized shares, each convertible into one common share and carrying 1% of the company’s diluted voting power.
Effective February 10, 2026, Bio-Path appointed Wendy M. Charles, PhD and Michael Hickey to its newly formed Scientific Advisory Board. Both entered three-year advisory agreements and each received 100,000 stock options with a $0.06 exercise price and a three-year expiration, subject to adjustment.